Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Dec;163(23-24):528-35.
doi: 10.1007/s10354-013-0219-z. Epub 2013 Aug 27.

Are There Differences in LDL-C Target Value Attainment in Austrian Federal States? Yes!

Free PMC article
Clinical Trial

Are There Differences in LDL-C Target Value Attainment in Austrian Federal States? Yes!

Max Pichler et al. Wien Med Wochenschr. .
Free PMC article


Low density lipoprotein (LDL-C) levels determine the cardiovascular risk. Previous studies indicated an LDL-C target attainment of around 50%, but no Austrian wide analysis on results for the federal states was available. We therefore sought to detect potential differences.

Design: Open-label, non-interventional, longitudinal study, registered: NCT 01381679. In all, 746 statin treated patients not at LDL-C goal received intensified therapy for 12 months. The sample was split into nine subgroups, representing the federal states of Austria.We detected an east-west gradient for baseline LDL-C. Individual target values were achieved by 37.2% (range: 26.1-57.7%). After 12 months, LDL-C < 70 mg/l was achieved by 13.5% (5.9-38.5%). Univariate ANCOVA retrieved significant differences within the states (Upper Austria and Salzburg, p = 0.001 and p = 0.0015, respectively). Furthermore, the capacity of intensified lipid lowering therapy applied in practice was as high as -42% as compared to previous standard therapy (additional LDL-C reduction after switch from baseline therapy in Vorarlberg).

Low Density Lipoprotein Cholesterin (LDL-C) Spiegel determinieren das kardiovaskuläre Risiko. Vorangegangene Studien zeigten eine LDL-C Zielwerterreichung von circa 50 %. Nachdem keine österreichweite geographische Analyse zur Zielwerterreichung verfügbar war, ermittelten wir, ob es Unterschiede zwischen den Österreichischen Bundesländern gibt. Design: Open-label, nicht-interventionelle, longitudinale Studie, registriert unter NCT01381679. 746 statinbehandelte Patienten, die ihren LDL-C Zielwert nicht erreichten, erhielten intensivierte Therapie. Die Stichprobe wurde in neun, die Österreichischen Bundesländer repräsentierenden, Subgruppen unterteilt. Ein Ost-West Gradient konnte für LDL-C zu Beginn der Studie festgestellt werden. LDL-C Werte < 70 mg/dl wurden von 13,5 % (5,9–38,5 %) der Patienten in Österreich nach 12 Monaten erreicht. Univariate ANCOVA zeigte einen signifikanten Unterschied zwischen den Bundesländern (Oberösterreich und Salzburg, p = 0,001, bzw. p = 0,0015). Die Kapazität intensivierter, in der Praxis angewandter, lipidsenkender Therapie betrug −42 % im Vergleich zu vorhergehender Standardtherapie (zusätzliche LDL-C Senkung nach Switch von der Therapie zu Beginn der Studie in Vorarlberg).

Trial registration: NCT01381679.


Fig. 1
Fig. 1
Attainment of low density lipoprotein cholesterol values <70 mg/dl (current target value as set by the major European societies) after 12 months
Fig. 2
Fig. 2
Low density lipoprotein cholesterol levels at baseline of the study (mg/dl), illustrating the described east west gradient in Austria

Similar articles

See all similar articles


    1. Anand SS, Islam S, Rosengren A, et al. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29:932–40. doi: 10.1093/eurheartj/ehn018. - DOI - PubMed
    1. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol. 1988;4:5A–10A. - PubMed
    1. Cholesterol Treatment Trialists’ Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81. doi: 10.1016/S0140-6736(10)61350-5. - DOI - PMC - PubMed
    1. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365:2078–87. doi: 10.1056/NEJMoa1110874. - DOI - PubMed
    1. Bogiatzi C, Spence JD. Ezetimibe and regression of carotid atherosclerosis: importance of measuring plaque burden. Stroke. 2012;43(4):1153–5. doi: 10.1161/STROKEAHA.111.640789. - DOI - PubMed

Associated data